Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
DLYE5953A · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Dose-Escalation Phase | EXPERIMENTAL | - |
| Dose-expansion cohort | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| DLYE5953A | DRUG | Escalating doses of DLYE5953A |
Inclusion Criteria: * Age \>/= 18 years * ECOG performance status of 0 or 1 * Histologically or cytologically documented advanced or metastatic solid tumors for which established therapy either does not exist or has proven ineffective or intolerable * Measurable disease by RECIST v1.1 with at least...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 5 | PHASE3 | ACE-536 |
| AbbVie, Inc. | ABBV | 4 | PHASE3 | Navitoclax, Ruxolitinib |
| Novartis AG Sponsored ADR | NVS | 3 | PHASE3 | Pelabresib, Ruxolitinib |
| Karyopharm Therapeutics, Inc. | KPTI | 4 | PHASE3 | Selinexor, Ruxolitinib |
| Geron Corporation | GERN | 2 | PHASE3 | Imetelstat |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Bomedemstat |
| Incyte Corporation | INCY | 10 | PHASE2 | Ruxolitinib |
| GSK plc Sponsored ADR | GSK | 2 | PHASE2 | MMB |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 1 | PHASE2 | Elritercept, Ruxolitinib |
| Eli Lilly and Company | LLY | 1 | PHASE1 | LY3410738, Venetoclax, Azacitidine |
| Disc Medicine, Inc. | IRON | 1 | PHASE1 | DISC-0974 |
| Galecto, Inc. | GLTO | 1 | PHASE2 | GB2064 |
| Prelude Therapeutics, Inc. | PRLD | 1 | PHASE1 | PRT12396 |
| United Therapeutics Corporation | UTHR | 1 | PHASE2 | bomedemstat |
DLYE5953A is an investigational small molecule being studied for the treatment of neoplasms, which are abnormal growths of tissue that can be benign or malignant. It is being evaluated in patients with refractory solid tumors, meaning tumors that have not responded to prior treatments. The drug is in clinical development for oncology indications.
DLYE5953A is being developed by Roche Holding AG, a multinational healthcare company. Roche's stock is traded under the ticker symbol RHHBY on the OTC market. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational oncology drug.
DLYE5953A is in Phase 1 of clinical development. This early-stage trial is designed to evaluate the safety of escalating doses of the drug in patients with refractory solid tumors. The Phase 1 study has been completed, and the drug remains investigational, meaning it has not yet been approved by regulatory authorities.
DLYE5953A has been studied in one clinical trial with the identifier NCT02092792. The trial was titled 'A Study Evaluating the Safety of Escalating Doses of DLYE5953A in Patients With Refractory Solid Tumors.' It was a Phase 1, controlled study conducted in the United States with 42 participants, all aged 18 years and older.
No, DLYE5953A is not FDA approved. It is an investigational drug that has completed a Phase 1 clinical trial. The trial focused on evaluating the safety of escalating doses in patients with refractory solid tumors. Since the drug is still in clinical development, it has not received approval from the FDA or any other regulatory agency.